Compare LMAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | NVCR |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 1.2B |
| IPO Year | 2006 | 2015 |
| Metric | LMAT | NVCR |
|---|---|---|
| Price | $97.78 | $17.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $105.80 | $28.08 |
| AVG Volume (30 Days) | 223.4K | ★ 1.8M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 30.57 | 21.79 |
| EPS | ★ 0.68 | N/A |
| Revenue | $249,602,000.00 | ★ $655,353,000.00 |
| Revenue This Year | $14.21 | $7.72 |
| Revenue Next Year | $8.88 | $6.74 |
| P/E Ratio | $146.62 | ★ N/A |
| Revenue Growth | ★ 13.53 | 8.28 |
| 52 Week Low | $79.01 | $9.82 |
| 52 Week High | $118.01 | $20.05 |
| Indicator | LMAT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 66.10 |
| Support Level | $82.65 | $12.48 |
| Resistance Level | $99.95 | $18.92 |
| Average True Range (ATR) | 4.66 | 0.90 |
| MACD | -0.63 | -0.08 |
| Stochastic Oscillator | 11.95 | 70.74 |
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.